BRPI0923085A2 - derivados de 3-(3-pirimidin-2-ilbenzil)-1,2,4-triazol[4,3-b]pirimidina - Google Patents

derivados de 3-(3-pirimidin-2-ilbenzil)-1,2,4-triazol[4,3-b]pirimidina

Info

Publication number
BRPI0923085A2
BRPI0923085A2 BRPI0923085A BRPI0923085A BRPI0923085A2 BR PI0923085 A2 BRPI0923085 A2 BR PI0923085A2 BR PI0923085 A BRPI0923085 A BR PI0923085A BR PI0923085 A BRPI0923085 A BR PI0923085A BR PI0923085 A2 BRPI0923085 A2 BR PI0923085A2
Authority
BR
Brazil
Prior art keywords
ylbenzyl
triazol
pyrimidin
pyrimidine derivatives
pyrimidine
Prior art date
Application number
BRPI0923085A
Other languages
English (en)
Inventor
Blaukat Andree
Dorsch Dieter
Stieber Frank
Schadt Oliver
Original Assignee
Merck Patent Ges Mit Beschraenkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschraenkter Haftung filed Critical Merck Patent Ges Mit Beschraenkter Haftung
Publication of BRPI0923085A2 publication Critical patent/BRPI0923085A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0923085A 2008-12-18 2009-11-18 derivados de 3-(3-pirimidin-2-ilbenzil)-1,2,4-triazol[4,3-b]pirimidina BRPI0923085A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008063667A DE102008063667A1 (de) 2008-12-18 2008-12-18 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
PCT/EP2009/008195 WO2010069441A1 (de) 2008-12-18 2009-11-18 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyrimidin-derivate

Publications (1)

Publication Number Publication Date
BRPI0923085A2 true BRPI0923085A2 (pt) 2019-09-24

Family

ID=41528195

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923085A BRPI0923085A2 (pt) 2008-12-18 2009-11-18 derivados de 3-(3-pirimidin-2-ilbenzil)-1,2,4-triazol[4,3-b]pirimidina

Country Status (15)

Country Link
US (1) US8563561B2 (pt)
EP (1) EP2358715B1 (pt)
JP (1) JP5576395B2 (pt)
KR (1) KR20110099742A (pt)
CN (1) CN102256980A (pt)
AR (1) AR074594A1 (pt)
AU (1) AU2009328730B2 (pt)
BR (1) BRPI0923085A2 (pt)
CA (1) CA2747287C (pt)
DE (1) DE102008063667A1 (pt)
EA (1) EA018750B1 (pt)
ES (1) ES2400112T3 (pt)
MX (1) MX2011006424A (pt)
WO (1) WO2010069441A1 (pt)
ZA (1) ZA201105257B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343977B2 (en) 2009-12-30 2013-01-01 Arqule, Inc. Substituted triazolo-pyrimidine compounds
US9796719B2 (en) * 2013-06-19 2017-10-24 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201321745D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321742D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DK0880508T3 (da) 1996-02-13 2003-06-30 Astrazeneca Ab Quinazolinderivater som VEGF-inhibitorer
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4－苯胺基喹唑啉衍生物
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
AU2001266232B2 (en) 2000-07-07 2005-09-15 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
CA2616604A1 (en) 2005-08-03 2007-02-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof
US7728017B2 (en) 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
PT1966214T (pt) 2005-12-21 2017-02-03 Janssen Pharmaceutica Nv Triazolpiridazinas como moduladores de tirosina quinase
WO2007138472A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
BRPI0717317A2 (pt) * 2006-10-23 2013-10-22 Sgx Pharmaceuticals Inc Modularoes da proteína cinase triazalopiridazina
DE102008028905A1 (de) * 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate

Also Published As

Publication number Publication date
ES2400112T3 (es) 2013-04-05
US8563561B2 (en) 2013-10-22
JP2012512200A (ja) 2012-05-31
MX2011006424A (es) 2011-07-20
KR20110099742A (ko) 2011-09-08
CA2747287C (en) 2017-01-03
EA201100941A1 (ru) 2012-01-30
EP2358715B1 (de) 2012-12-26
DE102008063667A1 (de) 2010-07-01
AU2009328730A1 (en) 2011-08-04
JP5576395B2 (ja) 2014-08-20
ZA201105257B (en) 2012-03-28
WO2010069441A1 (de) 2010-06-24
CA2747287A1 (en) 2010-06-24
US20110257172A1 (en) 2011-10-20
AR074594A1 (es) 2011-01-26
EA018750B1 (ru) 2013-10-30
EP2358715A1 (de) 2011-08-24
AU2009328730B2 (en) 2015-12-17
CN102256980A (zh) 2011-11-23

Similar Documents

Publication Publication Date Title
BRPI0811718A2 (pt) Derivados de 3,3-espiroindolinona
BRPI0917459A2 (pt) compostos de pirrol(2,3-d)pirimidina
IL206765A0 (en) 4,5-dihydro-oxazol-2-yl-amine derivatives
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
ZA201006475B (en) Heterocyclic derivatives
BRPI0907435A2 (pt) Derivados de 5-flúor pirimidina
BRPI0919948A2 (pt) Pirido[4,3-b]indois contendo porções rígidas
TWI348908B (en) Imidazolidinone derivatives
ES2465673T9 (es) Derivados de pirimidina
BRPI1014459A2 (pt) derivados de 3-(1,2,3-triazol-4-il)pirrolo[2,3-b]-piridina"
BRPI0816461A2 (pt) Derivados fungicidas de 2-alquiltio-2-quinolonolóxi-acetamida
DE602008005634D1 (de) 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
BRPI0914662A2 (pt) derivados de triazinona substituída
BRPI0914301A2 (pt) derivados de pirimidin-4-ona substituída
IL210592A0 (en) Novel substituted sulfamide derivatives
BRPI0920496A2 (pt) derivados substituídos de pirimidina etriazina
DE102008005493A8 (de) 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
BRPI0916363A2 (pt) derivados de 4,5-di-hidro-oxazol-2-ila
BRPI0820779A2 (pt) Derivados de 4-amino-pirimidina
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
BRPI0906714A2 (pt) Derivados de oxazepinopirimidona heteroarilamida substituídos.
ZA201002580B (en) Heterocyclic derivatives
BRPI0816679A2 (pt) Derivados de ftalazinona.
EP1992622A4 (en) 4- (3-benzoylaminophenyl) -6,7-dimethoxy-2-METHYLAMINOCHINAZOLINDERIVAT
BRPI0923085A2 (pt) derivados de 3-(3-pirimidin-2-ilbenzil)-1,2,4-triazol[4,3-b]pirimidina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.